Lunsumio (mosunetuzumab-axgb) - Roche
PBMC donor-dependent antitumor activity of mosunetuzumab in PBMC-humanized NXG B2m mice bearing Raji lymphoma is associated with distinct peripheral and intratumoral T-cell compositions. (SITC 2026) - Oct 2, 2026 - Abstract #3; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available 
Preclinical • Hematological Malignancies • Lymphoma • Oncology • B2M
https://www.sitcancer.org/2026/abstracts/titles-and-publications?SITC%202026%20Abstracts%5BhitsPerPage%5D=100
 
Olivier Déas; Julie Vendomele; Delphine Nicolle; Rouba Madani; Erwan Creach; Léa Sinayen
 
Oct 2, 2026
 
Prev Next